In hepatocellular carcinoma, cisplatin and 5-fluorouracil treatment enhance SPINK1 transcriptional activity and drive chemoresistance via the EGFR-ERK-CDK4/6-E2F2 axis (40, 46). Here, E2F2 is linked to hepatocellular carcinoma.